statistiche ricercatore

MORTARA, LORENZO

Distribuzione geografica

Continente	#
NA - Nord America	16.517
EU - Europa	14.534
AS - Asia	7.544
SA - Sud America	762
AF - Africa	147
OC - Oceania	29
Continente sconosciuto - Info sul continente non disponibili	18
AN - Antartide	1
Totale	39.552

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	16.239
IT - Italia	8.343
SG - Singapore	2.477
UA - Ucraina	1.796
CN - Cina	1.685
VN - Vietnam	1.079
HK - Hong Kong	842
TR - Turchia	811
FR - Francia	693
SE - Svezia	693
DE - Germania	679
BR - Brasile	638
FI - Finlandia	615
IE - Irlanda	487
GB - Regno Unito	376
RU - Federazione Russa	275
IN - India	179
BD - Bangladesh	148
NL - Olanda	137
CA - Canada	127
MX - Messico	116
JP - Giappone	93
PL - Polonia	76
ES - Italia	72
AR - Argentina	52
BE - Belgio	47
CH - Svizzera	46
AT - Austria	42
ZA - Sudafrica	41
IQ - Iraq	40
NG - Nigeria	40
CZ - Repubblica Ceca	31
PK - Pakistan	25
LT - Lituania	20
MY - Malesia	19
ID - Indonesia	18
PT - Portogallo	18
AU - Australia	17
EC - Ecuador	17
UZ - Uzbekistan	15
AE - Emirati Arabi Uniti	14
EU - Europa	14
SA - Arabia Saudita	14
CL - Cile	13
CO - Colombia	13
EG - Egitto	13
MA - Marocco	13
NZ - Nuova Zelanda	12
RO - Romania	12
MD - Moldavia	11
VE - Venezuela	11
NO - Norvegia	10
PY - Paraguay	10
IL - Israele	9
DZ - Algeria	8
KE - Kenya	8
TN - Tunisia	8
BG - Bulgaria	7
GR - Grecia	7
JO - Giordania	7
KR - Corea	7
PH - Filippine	7
TH - Thailandia	7
KZ - Kazakistan	6
NP - Nepal	6
BH - Bahrain	5
CR - Costa Rica	5
HU - Ungheria	5
LB - Libano	5
OM - Oman	5
SN - Senegal	5
AZ - Azerbaigian	4
BB - Barbados	4
HN - Honduras	4
RS - Serbia	4
TT - Trinidad e Tobago	4
BY - Bielorussia	3
DK - Danimarca	3
EE - Estonia	3
IR - Iran	3
JM - Giamaica	3
LU - Lussemburgo	3
MK - Macedonia	3
NI - Nicaragua	3
PE - Perù	3
PS - Palestinian Territory	3
SK - Slovacchia (Repubblica Slovacca)	3
UY - Uruguay	3
A2 - ???statistics.table.value.countryCode.A2???	2
AL - Albania	2
BA - Bosnia-Erzegovina	2
BF - Burkina Faso	2
CG - Congo	2
DM - Dominica	2
DO - Repubblica Dominicana	2
GT - Guatemala	2
MC - Monaco	2
ML - Mali	2
MT - Malta	2
QA - Qatar	2
Totale	39.521

Salva come PNG Salva come JPEG

Città	#
Milan	4.287
San Jose	1.625
Singapore	1.432
Jacksonville	1.342
Chandler	1.254
Ashburn	1.179
Fairfield	1.025
Hong Kong	822
Woodbridge	773
Ann Arbor	629
Houston	542
Dallas	498
Princeton	491
Dublin	481
Beijing	480
Wilmington	461
Dearborn	421
Rome	419
Izmir	400
Nyköping	379
The Dalles	379
Seattle	361
Boardman	358
Council Bluffs	353
Como	343
Cambridge	317
Dong Ket	314
Lauterbourg	251
Chicago	247
Los Angeles	247
New York	225
San Mateo	162
Ho Chi Minh City	159
Helsinki	146
Hanoi	145
Munich	103
San Diego	100
Kocaeli	93
London	92
Santa Clara	90
Ogden	84
Tokyo	77
Orem	75
Mexico City	73
São Paulo	73
Turin	73
Guangzhou	71
Varese	61
Buffalo	60
Turku	60
Warsaw	57
Chennai	55
Frankfurt am Main	53
Hefei	52
Florence	51
Verona	50
Düsseldorf	49
Brussels	43
Kunming	42
Manchester	42
Nanjing	40
Stockholm	40
Brooklyn	38
Denver	38
Genoa	38
Montreal	38
Atlanta	34
Bologna	34
Washington	34
San Francisco	33
Shanghai	33
Jinan	32
Johannesburg	32
Amsterdam	31
Abuja	30
Phoenix	30
Toronto	30
Boston	29
Norwalk	29
Salt Lake City	28
Nuremberg	26
Poplar	26
Bari	25
Da Nang	25
Pune	25
Hangzhou	24
Vienna	24
Brno	23
Palermo	23
Berlin	21
Tianjin	21
Fuzhou	20
Querétaro	20
Redmond	20
Des Moines	19
Zhengzhou	19
Brescia	18
Haiphong	18
Naples	18
Baghdad	17
Totale	25.729

Salva come PNG Salva come JPEG

Nome	#
Allergie e intolleranze. Icone di immunopatologia.	2.715
Polarization of Tumor Infiltrating Leukocytes from Innate Immunity and their role in the Pro-angiogenic Phenotype in NSCLC	307
Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer	300
Natural killer cells from patients with malignant or inflammatory pleural effusions display decreased cytotoxicity and decidual NK-like phenotype	282
Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?	252
Vitamin D Deficiency has a Negative Impact on Cetuximab-Mediated Cellular Cytotoxicity against Human Colon Carcinoma Cells	244
Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?	240
Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies	240
Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization	231
Grading of laboratories on CD4+T-lymphocyte evaluations based on acceptable data boundaries defined by the measurement error	229
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	226
Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response	226
Natural killer cells from patients with either malignant or inflammatory pleural effusions display decreased cytotoxic capacity and decidual-like phenotype	224
Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent anti-tumor effects	223
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS	222
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review	220
DC-SIGN from African green monkeys is expressed in lymph nodes and mediates infection in trans of simian immunodeficiency virus SIVagm	216
Acetyl-L-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways	216
CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions.	214
Positive role of macaque cytotoxic T lymphocytes during SIV infection: decrease of cellular viremia and increase of asymptomatic clinical period.	213
Recognition of antigenic clusters of Candida albicans by T lymphocytes from human immunodeficiency virus-infected persons.	213
The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer	210
T2 ribonuclease-mediated tumor suppression: an evolutionary conserved process involving a cross-talk between cancer cells and the immune system	208
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	207
Proffered Paper: The pro-angiogenic phenotype of natural killer cells infiltrating squamous cell carcinoma lung cancer	207
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	206
The human RNASET2 protein affects the polarization pattern of human macrophages in vitro	205
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	204
Orchestration of angiogenesis by immune cells	201
The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells	201
Analysis of Graves’ disease from the origins to the recent historical evolution	197
Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge.	196
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication	194
Microenvironment-mediated regulation of cancer growth by the human RNASET2 oncosuppressor gene	194
Early triggering of natural killer and dendritic cell during antitumor therapeutic response induced by TNFa tumor vessel delivery and melphalan	193
Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors	193
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment	193
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy	192
Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: Implications for immunotherapy	191
CD56(bright)CD16(-) NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4(+) T Cell Proliferation	189
Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression	188
Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene	188
The pro-angiogenic phenotype and functions of colorectal cancer tumour infiltrating (TINKs) and tumour associated (TANKs) natural killer cells	187
Regulation of macrophage differentiation and polarization pattern by human RNASET2 protein	187
Analysis of the antigen specific T cell repertoire in HIV infection	186
New strategies of mammary cancer vaccination	183
The story of a vitamin for bone health that upgraded to hormone for systemic good health.	183
Tumour infiltrating (TINKs) and tumour associated (TANKs) natural killer cells: a new paradigm in colorectal cancer angiogenesis	183
Schedule-dependent therapeutic efficacy of L19mTNF-a and Melphalan combined with Gemcitabine	182
Selection of virus variants and emergence of virus escape mutants after immunization with epitope vaccine	181
Early DC and NK cell activation during anticancer therapeutic response induced by TNFa tumor vessel delivery and melphalan	181
The rnaset2 oncosuppressor protein regulates both differentiation and polarization in human macrophages	177
Tumor vasculature targeted TNFα therapy: reversion of microenvironment anergy and enhancement of the anti-tumor efficiency.	175
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	171
Recognition of human T Leukaemia virus (HTLV-I) envelope by human CD4+ T cell lines from HTLV-I seronegative individuals: specificity and clonal heterogeneity.	170
The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: a focus on innate immunity cells as therapeutic eﬀectors	168
Natural killer cells from pleural effusions are responsive to interleukin-2 but are endowed with a potent pro-angiogenic feature	167
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation	167
Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves' disease patients during methimazole treatment	164
Biomedicine and traditional Chinese medicine: a fruitful scientific and cultural interaction.	163
Type 1 CD4+ T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptide vaccine in rhesus macaques.	162
A potential role of human RNASET2 overexpression in the pathogenesis of Graves’ disease	162
Analyse de DC-SIGN dans un modèle de résistance au SIDA	161
Prostate cancer peripheral blood NK cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production, and secrete monocyte-recruiting and polarizing factors.	160
Natural killer cells from malignant pleural effusion show a decidual-like phenotype and an alternative activatory state.	159
Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis	158
Plasmocytoid dendritic cell dynamics and alpha IFN production during Simian Immunodeficiency Virus infection with a nonpathogenic outcome	157
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	157
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy	156
Natural killer cells infiltrating colo-rectal cancer are switched towards the decidual-like pro-angiogenic CD56brightCD16- NK cell subset	156
Down syndrome, autoimmunity and T regulatory cells	152
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	151
Prolonged temporary remission in T1DM patients is associated to a distinctive Treg phenotype	150
STAT3 and STAT5 drive the pro-angiogenic NK cell polarization in colorectal cancer patients	150
Tumor infiltrating (TINKs) and tumor associated (TANKs) from colorectal cancer patients are proangiogenic and express angiogenin and the MMP9-TIMP2, similar to decidual NK cells	150
Pleural effusion NK cells from metastatic tumors display pro-angiogenic features and pleural effusion fluids block their response to IL-2 treatment	149
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells.	148
Innate immunity driving tumor angiogenesis: the role of natural killer cells in non-small cell lung cancer (NSCLC)	148
Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and Rejection	148
Analysis of the selection pressure by the NEF-immunodominant macaque CTL response in SIV infection	147
Early functional activation of natural killer cell and dendritic cell during the antitumor therapeutic response induced by TNFa tumor vessel delivery and melphalan	147
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions	145
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy.	145
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	144
Phenotypic and functional characterization of tumor infiltrating natural killer cells: role in tumor angiogenesis	144
Severità del Morbo di Basedow di prima diagnosi: ruolo dei linfociti Treg e dei micronutrienti. Dati preliminari di uno studio osservazionale pilota	144
The human RNASET2 alarmin-like molecule differentially affects prostate cancer cells behavior in both cell autonomous and non-cell autonomous manners	143
Phenotype and function of myeloid dendritic cells derived from African green monkey blood monocytes	143
The oncosuppressive role of RNASET2 gene in a mouse tumor syngeneic model	143
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy.	142
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	141
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	141
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients	141
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	140
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	140
Functional and phenotypic characterization of tumor infiltrating NK cells.	139
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan	139
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	138
Immune-mediated mechanisms in patients tested positive for SARS-CoV-2: Protocol for a multianalysis study	138
When a Friend Becomes Your Enemy: Natural Killer Cells in Atherosclerosis and Atherosclerosis-Associated Risk Factors	138
Totale	20.701

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	147.256
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	147.256

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	515	0	0	0	0	0	0	0	0	0	0	0	515
2021/2022	2.479	306	286	212	113	100	56	134	165	213	317	220	357
2022/2023	3.904	335	198	250	412	267	774	60	487	521	189	203	208
2023/2024	7.374	1.081	1.086	1.114	1.210	1.244	513	132	167	213	241	177	196
2024/2025	4.895	146	170	773	314	334	320	185	260	447	474	371	1.101
2025/2026	10.350	682	556	428	1.346	1.117	562	2.307	697	1.073	742	490	350
Totale													39.877